Safety Profile Comparison: Key Clinical Markers The following table outlines how common adverse events and safety considerations differ between GLP-1 formulations
Acceptable evidence includes any dated document or image issued within the past 30 dayssuch as a pharmacy dispensing label, electronic health-record screenshot, insurance explanation of benefits, clinical-trial visit summary, medication package showing a pharmacy sticker, refill receipt, or telehealth prescriptionprovided it clearly references a GLP-1 product (examples include semaglutide, liraglutide, dulaglutide, exenatide, lixisenatide, tirzepatide, or their brand or generic names)
It necessitated Mojsov injecting her lab-made peptides into rabbits once a week for three consecutive weeks to encourage their immune systems to produce specific antibodies against them which took about two months to happen (Mojsov, Heinrich, Wilson)
There have also been reports of diabetic retinopathy complications in patients with pre-existing retinal disease, necessitating appropriate monitoring and prompt reporting of visual changes
Won CH, Yoo HG, Park KY, Shin SH, Park WS, Park PJ
